$Esperion Therapeutics (ESPR.US)$Esperion initiated with an Overweight at Cantor Fitzgerald - TipRanks.com BELOW is a Detailed research report that should convince readers to have a portion of their investment portfolio in Esperion. This is not a pump article, please take the time to read and fact check.  This $2 stock will be $20+ by 2027.  Esperion anticipates Billions in Revenues.
Es...

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

This unique biotech   $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

$Plug Power (PLUG.US)$ Detailed Research Report in progress.  Notable new fund block buy 10 million share purchase filled 12/04
PLUG Power Ready For 2025 Price Target $8 Offers 300% Upside, A.i Power Play
$Plug Power (PLUG.US)$ PLUG power is now an attractive buy, we see more upside reward than downside risk.
Plug Power Inc. (NASDAQ:PLUG) Jefferies Renewables & Clean Energy Conference 2024 December 4, 2024
Company ...

$FuboTV (FUBO.US)$ $FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO is moving in the right direction with news yesterday Fubo Expands Sports, Entertainment, News and Latino Programming With Launch of 18 NBCUniversal FAST Channels
FUBO operates a live TV streaming platform for live sports, news, and entertainm...

$EVgo Inc (EVGO.US)$  Our Chart program alert shows a pull back below $6 within next 5 trading days is 70% likely.

$FuboTV (FUBO.US)$ We are reviewing FUBO T.V and we believe the current stock price doesn't reflect the true value. We believe a speculative investment in FUBO now offers more upside reward than downside risk.  
FUBO operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. The company's platform allows customers to acce...

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns   $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.  
This unique biotech     $Esperion Therapeutics (ESPR.US)$  Esper...